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Under the auspices of the Foundation for Excellence and Quality in Oncology (ECO), the Translational 
Research in Oncology Medical Services Study (INTRO) was conducted with the aim of describing the 
current state of, and future expectations for translational cancer research in Spanish medical centres. 
The first step in the investigation was intended to analyse the current condition of the national Medical 
Oncology Services network by examining different aspects of the oncology research field. 
Methods: A descriptive and observational multicenter study was performed at a statewide level; 
information was collected by surveying a cross-section of all those responsible for Medical Oncology 
Services in Spain.  
Results: The survey was completed by key-informants, who were selected independently by each 
service, between September 2010 and April 2011. We were able to gather comprehensive data from a 
total of 27 Spanish hospitals. These data enabled us to describe the allocation of human and material 
resources devoted to clinical and translational research across the Medical Oncology Services and to 
describe the organisational and functional components of these services and units. These data included 
information pertaining to the activities developed, their funding sources, and their functional 
dependence on other internal or external bodies. Finally we explored the degree of dissemination and 
use of some specific techniques used for the genetic diagnosis of cancer, which have recently been 
introduced in Medical Oncology within the Spanish health care system. 
Conclusions: A wide range of variability exists between different oncology services in Spanish hospitals. 
Time should be spent reflecting on the need and opportunities for improvement in the development of 
translational research within the field of oncology. 
Key words: Clinical ant translational research, Oncology services, Spanish Hospitals 
 
INTRODUCTION: 
The growth of knowledge in the field of oncology that has occurred in recent years is truly 
impressive. However in most cases, such progress has not resulted in changes in the treatment, 
prevention, or diagnosis of cancer, and has therefore produced a significant discrepancy between 



































































primarily by a distancing between basic research and clinical practice, which must be refocused more 
towards moving studies at the molecular or cellular level (bench) to patient treatments (bedside). This 
approach, called ‘bench to bedside’ is permeating all areas of medicine and especially so in the field of 
oncology. In scientific fields, and increasingly in the press, this is also referred to as ‘translational 
research’, and aims to accelerate the pace of the transfer of scientific discoveries made by basic 
research into clinical application. Translational research aims to go beyond the clinical trial to transfer 
concepts, ideas, and knowledge in a preliminary way, and may even include the use of animal models [1-
4].  
However, in Spain, the development of these initiatives remains, even today, largely symbolic. 
The report ordered and published by the Spanish government  in April 2002, regarding the call for 
assistance in the development of research networks, states:  “With regard to these groups of diseases 
(neoplastic, cardiovascular, neurodegenerative, and infectious, among others), the critical mass of 
researchers in our country is small and of low quality, they are fragmented and there are weak links 
between basic and clinical researchers, and between the research structures of the various institutions of 
the National Health System, universities, and public research organisations “ [5]. 
 
Some years have passed since this pessimistic prognosis, and the genuine status of the 
involvement of Medical Oncology Services in Spanish translational research is now unknown. This study 
analyses the issue, and provides points for reflection and professional debate on one of the undoubtedly 
most important lines of future development within the specialty.  
In this context it can be assumed that a possible variability factor between different centres and 
services may be the simple heterogeneity of physical and human resources, and the provision and 
availability of instrumentation within each unit, as key determinants of their research capabilities. 
Under the auspices of ECO Foundation, the INTRO study was conducted with the aim of 
describing the current experiences and future expectations for translational oncology research in 
Spanish health care facilities. It is a starting point in a course of action aimed at the analysis of the 




































































MATERIALS AND METHODS: 
Study Design: 
The study was a multicentre (statewide) descriptive and observational study, which collected 
information via a cross-sectional survey of those responsible for each of the Spanish Medical Oncology 
Services. The study was performed between September 2010 and April 2011, and consisted of survey 
completion by a key-informant, as determined at the discretion of each individual service surveyed. 
Each centre participated only once. 
Despite having previously established a process and procedures for the selection of medical 
oncology units to be surveyed, in order to develop a fully comprehensive study we decided to send 
surveys to every  Medical Oncology Service we could identify in Spain. A total of 62 surveys were sent, 
bringing together a large sample that was geographically dispersed throughout the country, which 
collected information from 27 oncology services (43.7%), and broadly represented the different 
characteristics of the largest centres in the various Autonomous Communities. 
No particular form of sample selection was carried out; instead units at all levels of healthcare 
were considered eligible for the study as long as they met the following criteria: 
 
 Medical Oncology services/units that were functionally active at the time of study, according to 
official health centre records in each autonomous region, within any type of health care 
organisation (public or private affiliation, or any other legal form of existing healthcare 
administration within the Spanish National Health System).  
 There was at least one physician specialising in Medical Oncology on their staff. 
 The manager (head of department or another equivalent senior position) expressly agreed with 
and consented to collaboration.  
 Centres agreed to provide all the information requested in the study questionnaire, and to 
authorise the use of such data, once collated, for the research purposes stated in the project 




































































The directors of all the eligible services identified were contacted directly with the aim of fulfilling 
our objective of 100% selected target recruitment. As an additional quality control criterion for 
recruitment, we reiterated to these healthcare providers that we were aiming to achieve a participation 
rate of not less than 80% of the oncology units/services contacted. 
 
Study objectives: 
The specific objectives of the study were: 
1.  To describe the allocation of human and material resources devoted to clinical and translational 
research in Spanish Medical Oncology Services. 
2.  To describe the organisation and basic operating of these services and units, including the 
activities undertaken, their sources of funding, and their functional dependence on other units/services, 
either located internally or externally. 
3.  To explore the degree of dissemination and use of some specific diagnostic techniques for the 
genetic diagnosis for cancer, which have recently been introduced into the Spanish health care setting 
within Medical Oncological Services. 
 
Study Material: 
In this project, the key-informants were deemed as those responsible for the services/units 
surveyed, or another reliable professional who was specifically delegated this representative task. In this 
case, a procedure was established where the formal unit supervisor had to check and confirm the 
information provided. 
The survey study was sent in an electronic format which could be filled out by each key-
informant through the ECO Foundation website (www.fundacioneco.es), or alternatively, the study 
surveys were also made available in a paper format (a printable PDF file). In this case the paper 
questionnaires were handled by staff specifically trained in questionnaire preparation, and were 
automatically scanned to ensure the accuracy of information capture, and to prevent errors in data 
collection. 
 




































































The INTRO project collected comprehensive data from a total of 27 of the 62 Spanish hospitals 
surveyed (43.7%). Based on the average size of the responding hospitals (809 beds) and the average 
number of doctors working in them (11 physicians) most of the data were obtained from large hospitals. 
Median size of the hospital, defined by the average number of beds per hospital, was 800 beds with a 
wide range from 95 to 1500 beds. Almost half of the hospitals studied had between 500-1000 beds (Fig 
1). 
 
Identification and General Characteristics of the Centres and Medical Oncology Services Surveyed 
The characteristics of each participating oncology service are described by their provision of 
human resources, physical space, the availability of communications and information technology 
equipment, the technical facilities in the day clinic (outpatient area), and the number of nursing 
consultations provided. Regarding human resources, there were an average of 11 physicians, 21 nursing 
staff, 15 auxiliary assistants, and 3 administrative assistants in the departments surveyed (Table 2).  
When describing the physical space available, the approximate area destinated to the day clinic 
in oncology services averaged 410 m2, with a median of 300 m2 and a wide range of between 35 and 
1500 m2. Outpatient clinics surface was 392 m2 on average, with a median of 200 m2, and a range of 
between 50 to 2000 m2. The vast majority of services (96.3%) had their own hospitalisation area 
(inpatient area). In addition, a further 42.3% could have inpatients hospitalised within other services. 
The median number of beds assigned for Medical Oncology was 24 [8-41]. 
The services had an average number of 8 consulting rooms that belonged exclusively to Medical 
Oncology [range: 6-23] and one-tenth of the departments surveyed (11%) shared consulting 
rooms/space with other services. Only 15 of the 27 participants in the survey were equipped with their 
own day clinic (Fig 2 and Fig 3). 
With regard to the availability of communications and information technology equipment, 
more than 90% of the clinics in different Medical Oncology units were provided with both a connection 



































































surveyed stated that they belonged to hospitals that kept electronic medical records, and only half of 
those said that they had already computerised their histories. 
Electronic prescribing systems were present in 70% of day clinics in Medical Oncology, and 78% 
had a patient/medication/dose identification system. 
Nursing consultations were available in 70% of the departments surveyed, and in most cases 
these were located in the day clinic (Fig 4a), in 50% of these cases the nurses’ primary tasks were mixed, 
and included both clinical and research assistance (Fig 4b). 
 
Infrastructure, Resources, and Research Activity in Medical Oncology Services 
Of the responding departments 75% (20 sites) had their own clinical research units, and 52% of 
these also possessed their own Translational Research (TR) Laboratories.  
The major source of funding for clinical research in Medical Oncology came from clinical trials, 
although in the majority of cases this was also supplemented with funds from public and private sources 
(Table 3). Referring solely to clinical trials, 23 of the 27 departments surveyed (85%) started a study of 
this type annually. Each year an average of 33 clinical trials were launched per service, with a median of 
30, ranged from 4 to 130 trials. Phase III clinical trials were the most commonly performed (45%), with 
Phase I trials accounting for only 9.9% of the total (Fig 5). 
Regarding the human resources data provided by the surveyed units, there was an average of 
one trainee and five clinical assistants per service linked to clinical and translational research. Together 
with clinical oncologists, other specialists dedicated to research in these units were biologists and 
chemists. 
Where a dedicated TR laboratory was not available, 95% of the services participated in TR 
activities in collaboration with other departments or units, either within the same hospital (such as 
within Pathology, Clinical Biochemistry, Pharmacology, Genetics, Immunology, Molecular Biology, 
Pulmonary-Thoracic and Gastrointestinal Surgery, and Haematology), or in other institutions (such as 
universities, cooperative groups, or alliances with other hospitals or research institutions). There was 
only one Oncology Service, from all of the respondents, which had specialist medical oncology 
physicians exclusively dedicated to TR. Most commonly there was an average of three or four physicians 



































































research personnel were biologists, biochemists, biotechnologists, nursing and pharmacy graduates, and 
laboratory technicians. Half of the TR laboratories had between one and two of these professionals 
working full time. Other contributors described by survey participants were students, senior technicians, 
healthcare assistants, laboratory technicians, and project managers. Three-quarters of the departments 
surveyed, with their own TR laboratories, had one or two dedicated technicians working there full time. 
Only three of the TR laboratories possessed administrative support staff, either full or part time, stably 
dedicated to TR. Half of the Medical Oncology Services that participated in this study had their own TR 
laboratory had a full-time TR data manager on staff, and the other 50% had one working part time. 
The approximate area occupied by TR laboratories in those services equipped with them, was 
140 m2 on average: 46.2% of them were located in a general research area and 30.8% of them in a 
specific dedicated area. All of the laboratories surveyed were equipped to perform cell culture 
techniques, genomics, and protein analysis, 90.9% of them had spectrophotometry and microarray 
equipment available, and 70% had gene cloning technology available to them. Within the genomics 
techniques available, all laboratories performed standard PCR and real-time PCR, and 85% of these also 
used sequencing techniques; in the latter 61.5 and 73% respectively shared this equipment with other 
laboratories. With regard to technical protein analysis: immunohistochemistry, Western blotting, and 1D 
and 2D gel techniques were performed in almost all the departments surveyed (92.3%, 92.3% and 84.6% 
respectively). In terms of physical and human resources provided, 43% of Medical Oncology Services had 
their own TR lab with access to the computerised clinical history records, and 46% of them also had 
quality certifications, both general and for specific techniques. 
 
In terms of scientific output, these laboratories had an average of 69 publications in the last five 
years (median 35), ranging between 5 and 326 publications. Of these publications, 54% were in the first 
impact factor quartile and 24% of them were in the second quartile. Focussing on hospital size and 
relating this to the number of clinical trials carried out, the existence of a molecular biology laboratory, 
or the number of annual publications: 13 of the 23 large hospitals (> 500 beds) reported having their 





































































Funding Translational Research Activities and Resources  
In 58% of cases, the major source of funding for the facilities and staffing of TR laboratories 
came from the public sector, and in 42% of these funding also came from the private sector. The sources 
of public funding were through state and local European funding agencies, and from the university; state 
agencies most often funded TR laboratories (83.3% of them received public funding). Regarding private 
funding sources, mainly this was shared by the pharmaceutical industry and by non-profit organizations 
and/ or foundations (Fig 6 and 7).  
The funding allocated to the employment of TR research staff came mainly from the private 
sector (55%), and within this, research foundations played a major role in providing funds for dedicated 
TR researchers in oncology. State funding agencies, which originate in the public sector (45%), were the 
main sources of funding for human resources in TR (70%), ahead of foundations and hospital research 
institutes. 
As for research project funding, 61% of funding came from the public sector, within which, 
most of it was obtained through national funding agencies, such as Instituto de Salud Carlos III and the 
autonomic/ regional health or research agencies were the primary fund providers. Private funding for 
cancer translational research was split between foundations and philanthropic funders (55.8%) and the 
pharmaceutical industry (39.1%).  
 
Relationship with the Hospital Administration and Translational Research Partnerships 
Almost 70% of Medical Oncology Service respondents claimed to have support for their 
investigation, on the part of the hospital management. 
All Medical Oncology services with their own TR laboratories had established alliances, both for 
clinical and translational investigation, with other service units, in particular with research centres, as 
well as with other hospitals. International external centres were used as strategic research alliances by 
only 40% of the services with their own TR laboratories. Specifically, they described partnerships with 
the DFCI, Harvard University, Oslo University, the Oncology Services in Aveiro (Portugal), Foggia 





































































Addendum on specific techniques 
Among the Specific techniques for genetic diagnosis of that have been recently transferred to 
the health care setting in Spain is the determination of KRAS gene, in the diagnosis of metastatic 
colorectal cancer. Of all the Medical Oncology Service respondents, 96.2% of them referred to 
performing this test, of which 80% performed it at their own centre. When samples were sent to other 
centres, it usually took them between 1 and 5 days to be sent, and the results were received with a 
delay of 7 to 10 days. In the centres performing the determination of the KRAS gene in situ, 47.6% 
performed it in the Pathology Department, and they had between one and two people dedicated to 
performing this technique. It took between 4 and 21 days (with a median of 7 days) to receive the test 
results when it was conducted at the centre. Most of the services (94%) determined KRAS mutational 
status by real time PCR, although 12% of the centres also performed direct sequencing techniques. 
The main sources of funding for this diagnostic test were the pharmaceutical industry and the 
hospital itself. All of the Oncology Services respondents reported that the technique should be 100% 
financed by the Spanish National Health Service (NHS) because it is a basic diagnostic technique that 
increases drug spending efficiency, as it is a predictive biomarker of drug response. 
The determination of the mutational status of EGFR gene in lung cancer was performed in 
92.6% of responding Oncology Services. Of these, the test was performed at the centre itself 60% of the 
time. Where it was carried out at a reference centre (40%) it took the sample between 1 and 5 days to 
be sent and between 3 and 15 days for the results obtained. When EGFR mutations were determined at 
the centre itself, it was most frequently performed in the Pathology Service, and to do so they dedicated 
between one and three people, usually one or two technicians and a qualified molecular biologist. The 
median time in which the results were received was 10 days (2-15 days). 
EGFR mutational status was determined by real time PCR in 81.3% of the services, with 25% 
also eventually performing sequencing techniques. At present, funding for the implementation of this 
technique mainly comes from the pharmaceutical industry (62.5%). With the same motivation as with 
the determination of mutations in KRAS gene, 96.2% of Oncology Services surveyed believed that the 
determination of EGFR mutations should be 100% subsidised by the NHS. 
The determination of amplification or over-expression of the ERBB2 gene in breast cancer is a 



































































addition to immunohistochemistry, 72% of the responding centers used FISH (fluorescent in situ 
hybridisation) and 46% CISH (chromogenic in situ hybridisation) techniques to determine its 
amplification or over-expression. 
 
DISCUSSION: 
Scientific progress often correlates with the economic and cultural development of a country. 
Over the past 25 years, biomedical research in Spain has significantly improved due to several factors.  
These include Spanish integration into the European Union and the consolidation of scientific policy at a 
national and European level, which have both contributed to a significant increase in research activity. 
However, the fraction of Gross Domestic Product (GDP) that is dedicated to research, development and 
innovation in Spain, which acts as a measure of a country's intellectual development, continues to be 
disappointingly low. Currently, Spain devotes the 0.89% of its GDP to research and innovation, whereas 
the average in the European Union is around 1.9%. [6] 
 
Whilst the relative number of researchers  in Spain has doubled over the last decade, the 
current ratio of 3.7 researchers per 1000 inhabitants of the economically active population is still 
considerably lower than the ratios of the  European Union  (5.1)  and the United States (7.4)  However, 
according to  bibliometric indicators, which determine the quality and quantity of scientific production, 
Spain is currently ranked eleventh on an international level, representing 2.8% of the world scientific 
production. A more detailed analysis of these figures shows that Spanish research groups linked to 
Universities are the main contributors to these scientific indicators (51%), followed by those attached to 
health institutions and hospitals (23%) and the Spanish National Research Council (13%),  even though, 
the precise percentages varying somewhat with geographical location. Thus, the contributions of health 
institutions have an important impact on Spanish scientific production, and undoubtedly, one of the 
most significant areas of their contribution is in cancer research. [6] 
Cancer represents a major disease burden in developed countries, with 16.7% of total healthy 
years lost in the EU-25. It is one of the most prevalent diseases in Spain and is, in fact, the leading cause 



































































accounting for 25.6% of all deaths and the annual incidence of new cases in Spain is about the 155,000. 
In terms of individual risk, one in three Spanish men and one in five Spanish women will be diagnosed 
with cancer at some point in their lifetime [7]. 
 
In recent years, new techniques in molecular biology, genomics, proteomics, and other 
disciplines have offered a continuous stream of discoveries. For this new knowledge to be translated 
into increased and improved prevention, diagnoses, and disease treatments, it is not enough to solely 
rely on the proper functioning of traditional channels that link the world of basic research and the 
clinical world. The purpose of so-called translational research (otherwise known as research transfer) is 
to encourage and facilitate this relationship, accelerating the process of knowledge transfer and making 
it more productive. 
Understandably, patients are in a hurry, and research aimed at solving their problems is often 
slow and, to a large extent, has its own intrinsic rhythms which cannot be accelerated, both in basic and 
in clinical phases. However, there are more stages in the journey from the laboratory to the patient than 
just basic experimentation and clinical trials. For example, the ease with which a basic researcher can 
make an observation and recognise that it may be useful in the clinic; the speed at which information 
can be accessed from human patients, or how fast a basic or clinical research group can overcome 
bureaucracy to reach a development agreement with a company. Lenfant summarised this in a paper 
published in the New England Journal of Medicine in 2003: "The transfer of knowledge from the shelves 
into practice, making it accessible to doctors and patients, and the achievement of an authentic 
marriage of knowledge with intuition and good judgment ... all that requires transfer" [8]. The editors of 
the Journal of Translational Research also clearly explained the problem: "[...] when new therapies find 
their way through preclinical testing, clinical trials, and the Phase III studies, they have often ceased to 
be 'state of the art'. They may even be scientifically obsolete." [9]. In response to these problems, some 
hospital and university research and development (R&D) departments in Canada, the home of 
translational research, have made the integration of drug discovery and development a priority [10, 11]. 
From there, the so-called "bench to bedside" approach has spread throughout the scientific world, in a 



































































Over the past few decades, basic science researchers have worked in isolation to unravel the 
cellular and molecular mechanisms involved in cancer development, while clinical researchers have 
studied the effects of new drugs and other treatments in cancer patients. Nevertheless, in recent years 
major efforts have been made to align these two tasks, and to translate laboratory findings so as to 
develop increasingly more effective anti-tumoral treatments. However, the development of new cancer 
treatments requires a previously unseen level of integration in all aspects of basic and clinical research, 
requiring the obsolete and artificial barriers that divide different groups of scientists to be abandoned 
[12, 13]. 
In Spain, the development of basic and translational cancer research has undergone significant 
structural changes over the past two decades. Initially, research was carried out in isolation, by specific 
groups in certain centres, the number of which was steadily increasing. These groups were principally 
found in hospitals, universities and in groups belonging to the Spanish National Research Council (known 
as CSIC). As an example of the little attention paid to cancer research in the past, it is remarkably that 
the first Congress of Cancer Research was not held until 1982, when a group of pioneers met in Madrid 
to highlight the urgent need for the implementation of a government scientific policy to facilitate the 
development of basic, applied, and clinical cancer research [14, 15]. Fortunately, in the late 80's and 
early 90's, the situation in clinical research started to change, among other factors, aided by the 
influence exerted by the introduction of the National Plan for R&D, which provided explicit support for 
oncological investigation [14]. However, even today the development of these initiatives seems to be 
symbolic in Spain, with few researchers, and inadequate links between basic and clinical investigation, 
the various institutions in the Spanish NHS organisations, and universities etc.  
 
In 1995, the Spanish Association of Cancer Research (ASEICA) published its first directory of 
oncology research units, comprising a total of 63 groups. Between 1996 and 2001, the number of active 
groups was 73, revealing a growing trend. Furthermore, in the same period, 13 specialized centres were 
established in Spain, which were exclusively dedicated to cancer research. 
 
The first initiative for the establishment of research activities in networks was settled in 2002, 



































































Research. Since then, there was an evolution in the experiences of cooperative cancer research 
networks in Spain until its present organization. The main objective of this kind of research networks is 
to improve the synergyzation and the enhancement of the quality of cancer research performed by 
individual groups at the national level.  There was an initial Network of Cancer Research Centers 
(RTICCC) established during the years 2003-2006 that encompassed 23 research centers located on 12 
autonomous regions of Spain. In 2006, the model was switched from the research centers to the 
individual groups and a new network was established, the RTICC which involved the cooperative work of 
95 research groups distributed in institutions located in 13 different autonomous regions. The RTICC 
activities have been extended for a total of 6 years until the end of 2012. The current RTICC has a new 
organization and consistently with the significantly reduced budget, there are only 70 groups 
participating in this new collaborative structure (www.rticc.org). 
 
Between 1998 and 2008, spending on I+D+i in Spain tripled, but the cuts of recent years (more 
than 40% since 2009) have pushed back to I+D+i at the levels of a decade ago. The health and social 
services budget was reduced by 13.65% in 2012, with disproportionately high cuts professional training 
(75%) and public health and quality programmes(45%). These budgetary changes were accompanied by 
a structural change that was introduced, unusually, not after parliamentary debate, but by a royal 
decree. The controversial Spanish Research strategy and development plan 2013-2020 and the state of 
I+D that implements it, pursue the one hand reduce public support for basic research and education and 
bring to applied research, market-oriented, encouraging private participation. In addition, today we 
have a very distorted view of how the I+D+i, since in any developed country is built applied research and 
innovation by competition with basic research.[16] 
 
At present, the status of real involvement of Spanish Medical Oncology Services in translational 
research activity is unknown, therefore we aimed to analyse the issue with this study. We found that a 
great variability exists between different Spanish hospitals, as measured by the considerable 
heterogeneity in physical and human resources and instrumentation available in each unit, as major 



































































One noticeable feature that emerged from the data regarding unit characteristics was that only 
55.5% of the oncology service respondents possessed their own day clinics, and of those 11% of them 
shared consulting space with other services. In terms of technology, we noted that 90% of oncology 
services had access to the computer network and internet access, and 70% of the day clinics worked 
with electronic prescribing. In terms of research, it stood out that 75% of the departments surveyed had 
their own clinical research units, but only 52% of them had their own translational research laboratories, 
and if we look only at Level 1 hospitals (with more than 500 beds) only half of them (56%) had their own 
TR laboratories. Most of the research staff funding came from clinical trials and 85% of respondents had 
clinical trials underway, although only 9.9% of those being conducted were Phase I trials. On average, 34 
clinical trials start in large hospitals annually. As for specialists working in TR laboratories, there was a 
wide variation; only one of the services had a full-time clinical oncologist completely dedicated to 
investigation, in the remaining they worked part-time, and only 37% of services reported having at least 
one biologist on their staff. Only 11 of the 23 Level 1 hospitals (47.8%) reported having published in the 
last 5 years. 
With these data, the INTRO study has helped us to take a snapshot of the current structural and 
organisational situation in TR in the various Spanish Medical Oncology Services. This has allowed us to 
realise that great variability exists among different Spanish hospitals, and helps us to reflect on the need 
and possibilities for improvement in translational research in the speciality. We cannot explore if a 
dichotomy exists between large and small hospitals nationally, since most of the hospitals that 
participated in the study (85.2%) were Level 1 (>500 beds). However, we can highlight the fact that only 
56.5% of these hospitals possessed their own TR laboratories, and that we only have data on 
publications in the last 5 years in 11 of 23 of the participating units (47.8%). 
 
Following our analysis of the current state of basic and translational research in Spain, in which 
we have taken into account the rapid rate of development over the past few years, several aspects have 
proven to be unsettling. 
There is no doubt that the progress achieved in recent years has resulted from an increased 
financial investment in research, however, to consolidate this trend, it is necessary to continue to 



































































important emerging sources of funding. Yet, today there are still financially neglected areas of research, 
such as clinical trials sponsored by collaborative research groups that, in the absence of financial 
support from state agencies, depend almost exclusively on the pharmaceutical industry. 
Parallel to the requisite increase in funding, it is imperative to have a solid strategy that outlines 
comprehensive plans for the development, financing and promotion of cancer research. These plans 
should comprise an overview of the epidemiology, prevention and management of the diagnosis and 
treatment of the disease at all levels, and should also cover aspects of basic, translational and clinical 
research. Furthermore, within the NHS Hospital System, investment in research, facilitating the 
development of scientific programs, must be promoted, so as to create research jobs within hospital 
complexes and to engender the attitude that research provides an added value that brings prestige to 
institutions. 
We believe that the ‘handing over’ of healthcare to the Autonomous Regions, albeit with clear 
advantages for the management of Health Services, is also causing a growing divergence in the local 
standards of each Autonomous Community, including within each individual health centre. These 
standards help determine the provision for, and operation of these health care units, and the resources 
dedicated to the research carried out in them. A problem that arises from such imbalances in provision 
is the influence on healthcare professionals and their involvement with the healthcare organisations on 
which they depend, including their degree of motivation to improve their practices within these 
organisations. Recent data from all types of medical specialties show a high prevalence of burnout 
among medical professionals, a fact associated with, among other factors, the perception of the limited 
career possibilities and deficiencies in the physical conditions and facilities available in the workplace. 
Among other possible motivation factors, participation in quality research activities is generally 
recognised as a powerful incentive for clinicians in the different specialties that have been analysed. 
As the ECO Foundation, we strongly believe that investing in research is profitable in the short 
and long term. We need a reliable, internationally-compatible research strategy that takes advantage of 
all available resources, scientific or clinical, increasing investment in both staff and materials. The 
hospital environment is required for translational research, and such research confers  
Within this setting, the ECO Foundation has several valuable reasons for promoting this project: 



































































research, secondly the desire to promote positive competition among units to form benchmark 
processes (replication of best clinical, organisational, or scientific practices). Last, but not least, 
upholding the mandate of conduct which commits all health professionals to continually improve the 
services they provide, an impossible task without quality translational research. 
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TABLE 1: Variables and Measurements 
1. Identification and general characteristics of 
the Medical Oncology Services surveyed. 
 Human resources  
 Physical space  
 Approximate area 
 Provision of information, 
communications, and other technologies 
 Structure of clinical and/or translational 
investigation  
2. Infrastructure, resources provided and 
research activity. 
 
2.1 For Clinical Research (personnel, funding, activity) 
2.2. For Translational Research (TR): 
 
 
 Availability of the clinical research unit in 
the Medical Oncology Service. 
 Availability of IT in the laboratory. 
 Dedicated physical space. 
 Quality Certifications. 
 Resources provided/techniques 
available: 
a. Cell culture. 
b. Genomics: PCR and sequencing. 
c. Protein analysis. 
d. Spectrophotometry. 
e. Others. 
 Research staff: number and dedication to 
TR. 
 Professional categories and academic 
training. 
 Publications. 
3. Sources of TR funding in the unit: fiscal, EU 
programs, other public funds, private funding 
(pharmaceutical industry, foundations, etc.), 
other sources (university, etc.). 
 Self-financing of TR within the laboratory 
(facilities, staffing). 
 Funding for the employment of TR 
researchers. 
 Financing of TR projects. 
4. Relationship with the hospital administration, 
collaboration with other services and other 
agencies 
 Perception of TR and its support from the 
management (yes/no). 
 Independence of the laboratory 
(shared/own). 
 Partnerships internal/external to the 
hospital (yes/no). 
5. Addendum: availability, use and service 
financing of specific genetic diagnosis techniques 
recently transferred to the Spanish healthcare 
setting 
 The K‐ras gene in metastatic colorectal 
cancer (MCRC). 
 The EGFR gene in lung cancer. 



































































 TABLE 2: Human Resources in the Medical Oncology Service Departments Surveyed 
Human Resources Mean Median 
Std. 
Dev. 
P25 P75 Range 
Nº of Doctors 11 11.0 5.20 10.0 13.0 29 
Nº of Nurses 21 18.0 10.75 14.8 25.3 44 
Nº of Clinical Assistants 15 15.0 7.59 10.0 19.0 29 
Nº of Other Healthcare Personnel 1.5 1.0 0.80 1.0 2.0 4 
Nº of Administrative Assistants 3 3.0 1.89 2.0 4.8 7 






































































 TABLE 3: Sources of Personnel Funding (Percentage Distribution) 
 
Sources Mean Median 
Clinical Trials 61.6 72.5 
Private Funds 22.1 10 





































































Fig 1: Hospital size based on the number of beds, grouped 
Fig 2: Consulting Rooms Shared with Other Services  
Fig 3:  Outpatient Clinic 
Fig 4: A) Location of Nursing Consultations, B) Work Carried Out by Nurses  
Fig 5: Types of Clinical Trials Performed in Each Medical Oncology Service (% Mean). Categories are 
not Exclusive 
Fig 6: Public Sector Fundings (% of Services that Declared their Sources. Categories are not Exclusive;  
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